We are live on ! Find out more
URGN icon

UroGen Pharma
URGN

74 hedge funds and large institutions have $497M invested in UroGen Pharma in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

280% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 10

209% more call options, than puts

Call options by funds: $1.38M | Put options by funds: $447K

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

20% more capital invested

Capital invested by funds: $413M → $497M (+$84.3M)

17% more funds holding

Funds holding: 63 → 74 (+11)

6.2% more ownership

Funds ownership: 59.54% → 65.73% (+6.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
74
Holders Change
+11
Holders Change %
+17.46%
% of All Funds
1.6%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
20
Increased
38
Reduced
10
Closed
9
Calls
$1.38M
Puts
$447K
Net Calls
+$935K
Net Calls Change
+$587K

Top Buyers

Rank Fund Capital Flow
1
HCM
Highline Capital Management
New York
+$22M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$20.1M
3
MMH
Menora Mivtachim Holdings
Israel
+$19.1M
4
MIFH
Migdal Insurance & Financial Holdings
Israel
+$14.8M
5
SFM
Sphera Funds Management
Israel
+$12.9M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$8.58M
2
PFO
Pathstone Family Office
New Jersey
-$1.67M
3
MCM
McKinley Capital Management
Alaska
-$726K
4
UOC
UBS O'Connor
Illinois
-$700K
5
Wells Fargo
Wells Fargo
California
-$653K
Name Holding Trade Value Shares
Change 		Change in
Stake
TEE
26
Tibra Equities Europe
United Kingdom
$1.26M +$1.43M +34,087 New
Swiss National Bank
27
Swiss National Bank
Switzerland
$1.19M +$587K +14,000 +77%
Barclays
28
Barclays
United Kingdom
$1.13M +$389K +9,282 +44%
Norges Bank
29
Norges Bank
Norway
$1.11M +$1.26M +30,000 New
Northern Trust
30
Northern Trust
Illinois
$968K +$360K +8,596 +49%
Morgan Stanley
31
Morgan Stanley
New York
$920K +$413K +9,856 +65%
AS
32
Altshuler Shaham
Israel
$912K – – –
BHB
33
Bank Hapoalim BM
Israel
$891K +$1.01M +24,125 New
Bank of America
34
Bank of America
North Carolina
$717K +$736K +17,553 +938%
Assenagon Asset Management
35
Assenagon Asset Management
Luxembourg
$655K +$337K +8,033 +83%
Geode Capital Management
36
Geode Capital Management
Massachusetts
$575K +$312K +7,450 +92%
DCM
37
DAFNA Capital Management
California
$554K – – –
JMPWA
38
JP Morgan Private Wealth Advisors
California
$537K +$12.3K +293 +2%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$510K – – –
Squarepoint
40
Squarepoint
New York
$489K +$555K +13,240 New
ECM
41
ExodusPoint Capital Management
New York
$451K +$512K +12,208 New
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
$444K +$230K +5,495 +84%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$439K +$193K +4,614 +64%
AWM
44
Avitas Wealth Management
California
$437K -$29.9K -713 -6%
EMG
45
ETF Managers Group
New Jersey
$433K -$15.8K -377 -3%
CSS
46
Cubist Systematic Strategies
Connecticut
$415K +$438K +10,438 +1,305%
CBA
47
Coastal Bridge Advisors
Connecticut
$369K +$419K +10,000 New
TCIM
48
TIAA CREF Investment Management
New York
$358K +$126K +3,003 +45%
Deutsche Bank
49
Deutsche Bank
Germany
$338K -$269K -6,421 -41%
AIM
50
ARK Investment Management
Florida
$333K -$96K -2,291 -20%
1
2
3 4

URGN Hedge Fund Activity: Q1 2019 in Review

74 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2019, worth a combined $497M — up 20% from $413M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new URGN positions and 9 closed out — a net gain of 11 holders — while 38 added to existing stakes and 10 trimmed.

The largest buyer was Highline Capital Management, adding an estimated $22M. The largest seller was Citadel Advisors, cutting an estimated $8.58M.

  • 74 institutional investors held UroGen Pharma (URGN) as of Q1 2019, up from 63 in Q4 2018.
  • Funds reported $497M of UroGen Pharma stock for Q1 2019, up 20% quarter-over-quarter.
  • 20 funds opened new UroGen Pharma positions in Q1 2019 and 9 closed out, a net change of +11 holders.
  • The largest UroGen Pharma buyer in Q1 2019 was Highline Capital Management, an estimated $22M added.
  • The largest UroGen Pharma seller in Q1 2019 was Citadel Advisors, an estimated $8.58M sold.

Based on aggregated 13F filings for Q1 2019.